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Background: Polyfluoroalkyl chemicals (PFCs) such as perfluorooctane sulfonate (PFOS) and 
perfluoro octanoate (PFOA) have been associated with early menopause. However, previous cross-
sectional studies have lacked adequate data to investigate possible reverse causality (i.e., higher 
serum concentrations due to decreased excretion after menopause).
oBjectives: We investigated the association between PFOS, PFOA, perfluorononanoate (PFNA), 
and perfluorohexane sulfonate (PFHxS) and age at natural menopause among women 20–65 years 
of age in NHANES (National Health and Nutrition Examination Survey).
Methods: We used proportional hazard models to estimate hazard ratios (HRs) for the onset of 
natural menopause as a function of age and serum PFC levels, and to investigate reverse causation 
by estimating associations between PFC levels and the rate of hysterectomy. We also used multi-
variable linear regression to determine whether time since menopause predicted serum PFC levels.
results: After adjusting for age at survey, race/ethnicity, education, ever smoking, and parity, 
women with higher levels of PFCs had earlier menopause than did women with the lowest PFC 
levels. We observed a monotonic association with PFHxS: The HR was 1.42 (95% CI: 1.08, 1.87) 
for serum concentrations in tertile 2 versus tertile 1, and 1.70 (95% CI: 1.36, 2.12) for tertile 3 
versus tertile 1. We also found evidence of reverse causation: PFCs were positively associated with 
rate of hysterectomy, and time since natural menopause was positively associated with serum PFCs.
conclusions: Our findings suggest a positive association between PFCs and menopause; however, 
at least part of the association may be due to reverse causation. Regardless of underlying cause, 
women appear to have higher PFC concentrations after menopause.
citation: Taylor KW, Hoffman K, Thayer KA, Daniels JL. 2014. Polyfluoroalkyl chemicals 
and meno pause among women 20–65 years of age (NHANES). Environ Health Perspect 
122:145–150; http://dx.doi.org/10.1289/ehp.1306707
Introduction
Polyfluoroalkyl chemicals (PFCs) are man-
made compounds that have been used in a 
number of common consumer and industrial 
products such as food containers; stain- and 
water-resistant protection for clothing, furni-
ture, and carpets; paints; fire-fighting foam; 
and photographic emulsifiers (Lau et al. 
2007). PFCs are ubiquitously present and per-
sistent in the environment (Lau et al. 2007), 
and although there are demographic, geo-
graphic, and temporal differences, exposures 
in the general population are widespread. 
Four PFC analytes—perfluoro octane sulfo-
nate (PFOS), perfluoro octanoate (PFOA), 
perfluoro nonanoate (PFNA), and perfluoro-
hexane sulfonate (PFHxS)—are commonly 
detected in humans (Calafat et al. 2006; 
Fromme 2007; Kato et al. 2011). Unlike 
traditional persistent organic pollutants, 
which are lipophilic and stored primarily in 
fat tissue, PFOS and PFOA are both lipo-
phobic and hydrophobic. After absorption, 
they persist in the body by forming chemi-
cal bonds to proteins in serum, rather than 
accumulating in lipids (Jones et al. 2003; 
Organisation for Economic Co-operation and 
Development 2002). Serum levels of PFCs 
reflect long-term exposures to these contami-
nants [U.S. Environmental Protection Agency 
(EPA) 2012b], with estimated geometric 
mean half-lives of 7.3 years (95% CI: 5.8, 9.2) 
for PFHxS, 4.8 years (95% CI: 4.0, 5.8) for 
PFOS, and 3.5 years (95% CI: 3.0, 4.1) for 
PFOA (Olsen et al. 2007). However, in a 
more recent study, Bartell et al. (2010) esti-
mated a shorter median half-life for serum 
PFOA (2.3 years; 95% CI: 2.1, 2.4). 
PFCs are potential endocrine disruptors, 
and effects of PFOS and PFOA on endo-
crine function have been reported in animal 
studies (Jensen and Leffers 2008; Zhao et al. 
2010). Less is known about associations 
between PFCs and human endocrine func-
tion. Melzer et al. (2010) reported that higher 
concentrations of serum PFOA and PFOS 
were associated with current thyroid disease 
based on NHANES (National Health and 
Nutrition Examination Survey) data from 
1999–2000, 2003–2004, and 2005–2006. 
In addition, in a population-based cohort of 
adolescents and young adults in Taiwan, Lin 
et al. (2013) observed a positive association 
between serum levels of PFNA and serum 
levels of thyroxine (T4). Yet, other studies 
have reported no association between PFOS 
or PFOA levels and thyroid function. These 
include occupational studies with high levels 
of exposure (Olsen et al. 2003; Olsen and 
Zobel 2007); a study of residents of a water 
district in south eastern Ohio, where there is 
significant environmental exposure to PFOA 
(Emmett 2006); studies of popula tions in 
Korea (Ji et al. 2012) and China (Lin et al. 
2013); a study of Inuit adults (Dallaire et al. 
2009); and studies of pregnant women (Chan 
et al. 2011; Inoue et al. 2004). In the United 
States, one of the largest efforts to investigate 
the impact of exposures to PFCs was initiated 
by the C8 Science Panel, which was created 
as part of a settlement agreement stemming 
from PFOA (or C8) contamination of drink-
ing water in six water districts in two states 
near the DuPont Washington Works facil-
ity near Parkersburg, West Virginia (Frisbee 
et al. 2009). In this exposed popu la tion, high 
environmental levels of PFOA in water were 
associated with delayed onset of puberty in 
girls (Lopez-Espinosa et al. 2011) as well as 
earlier menopause (Knox et al. 2011). Knox 
et al. (2011) found that serum PFOS and 
PFOA were significantly higher (p < 0.0001) 
in women 40–55 years of age who had a hys-
terectomy compared with women who had 
not. However, because the authors did not 
observe the timing of PFC exposure relative 
to menopause, causal inference is limited. 
One non causal explanation for an association 
between PFCs and natural meno pause is that 
elimination of PFCs via the loss of menstrual 
blood and tissue might result in lower serum 
levels in menstruating women than in post-
menopausal women (Knox et al. 2011). 
We investigated associations between 
multiple PFCs (PFOS, PFOA, PFNA, and 
PFHxS) and age at natural and surgically 
induced (hysterectomy) meno pause using 
NHANES data. NHANES collected informa-
tion regarding the age at which women 
experienced menopause, which allowed us 
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to investigate the relationship between serum 
levels and time since menopause and the 
possibility of reverse causality.
Methods
Study population. NHANES is a nationally 
representative, cross-sectional survey of about 
5,000 persons each year, with survey partici-
pants located in counties across the United 
States. The survey uses in-home interviews 
and physical examinations in a mobile exami-
nation unit to collect data on demo graphics, 
behavioral and environmental risk factors, and 
health status [Centers for Disease Control and 
Prevention (CDC) 2012]. Written consent 
was obtained from all NHANES partici-
pants after approval by the NCHS (National 
Center for Health Statistics) Research Ethics 
Review Board (CDC 2012). Details regarding 
interview, examina tion, and sample collec-
tion proto cols have been described previously 
(CDC 2013a). Because the present study is 
based on previously collected data that have 
been deidentified, the University of North 
Carolina Institutional Review Board deter-
mined the study to be exempt from review. 
PFC measurement. The National Center 
for Environmental Health analyzed individual 
serum PFC levels in five NHANES sample 
waves: 1999–2000, 2003–2004, 2005–2006, 
2007–2008, and 2009–2010. In each wave, 
a random one-third subset of partici pants 
≥ 12 years of age was selected for assess ment 
of 12 PFCs (CDC 2009). Detailed analytic 
methods have been described previously 
(Calafat et al. 2007a, 2007b; Kato et al. 2011). 
Briefly, serum samples were analyzed using 
automated solid-phase extraction coupled 
to reverse-phase high-performance liquid 
chromatography/tandem mass spectrometry. 
The laboratory methods and comprehensive 
quality control system were consistent across 
each NHANES wave, and documenta-
tion for each wave is available online (CDC 
2013b). We examined PFOS, PFOA, PFNA, 
and PFHxS in relation to menopausal status 
because these com pounds were detected in 
> 95% of samples compared with other PFCs, 
which were detected infrequently (Calafat et al. 
2007a, 2007b; Kato et al. 2011). Any partici-
pant with a serum PFC concentration below 
the limit of detection (LOD) was assigned a 
serum level of the LOD divided by the square 
root of 2 (Calafat et al. 2007a, 2007b; Kato 
et al. 2011). Serum PFC concen tra tions were 
categorized into tertiles based on distributions 
among all women in the study sample. We 
considered other categoriza tions, including 
quartiles and quintiles, but results were similar 
regardless of the categoriza tion used (results 
not shown). We chose to catego rize by tertile 
to increase the stability of our estimates.
Menopausal status. Women ≥ 18 years 
of age completed a reproductive health 
questionnaire. They were asked “Have you 
had at least one menstrual period in the past 
12 months? (Please do not include bleedings 
caused by medical conditions, hormone ther-
apy, or surgeries.).” Women who answered 
“no” were subsequently asked “What is the 
reason that you have not had a period in the 
past 12 months?” We classified women as 
premenopausal if they answered “yes” to the 
first question or answered “no” to the first 
question but indicated the reason as preg-
nancy, breastfeeding, irregular periods, or 
medical conditions/treatments (n = 1,800). 
We classified women as post menopausal if 
they answered “no” to the first question and 
indicated the reason to be natural meno pause 
(n = 501) or hysterectomy (n = 431). We 
excluded from all analyses 265 women with 
no information on their menopausal status 
and 14 who answered that they had not had 
their period in the last 12 months but did 
not state why (Figure 1). The distribution of 
demo graphic characteristics and PFC levels 
among these women were similar to those 
of the combined larger sample, except that 
most women were missing data for parity. For 
women who reported having gone through 
menopause, age at occurrence was recorded. 
We calculated time since menopause by sub-
tracting the age at which post menopausal 
women reported having their last menstrual 
period from their age at the time of survey.
Statistical analyses. We used proportional 
hazard modeling to estimate hazard rate 
[hazard ratios (HRs)] of the onset of natural 
menopause as a function of age and serum 
PFC levels. Premenopausal women were cen-
sored at their age at the time of the survey. 
Analyses were performed in SAS (version 9.2; 
SAS Institute Inc., Cary, NC) using the Proc 
SURVEYPHREG procedure, which accounts 
for stratification and clustering within primary 
sampling units used to select the NHANES 
sample. Rather than using NHANES sample 
weights, we adjusted all models for covari-
ates related to the NHANES sample selection 
procedure (age and race/ethnicity), a method 
that balances the trade-off between efficiency 
and bias (Graubard and Korn 1999; Korn and 
Graubard 1991). To determine the robust-
ness of our results, we also conducted analy-
ses using the NHANES sample weights. The 
inclusion of weights made no appreciable dif-
ference in the magnitude or precision of the 
associations (results not shown); therefore, we 
present the unweighted analyses.
Covariates. We considered a number 
of covariates as possible confounders in the 
association between PFCs and menopause. 
We used information on the association 
between other persistent organic pollutants and 
menopause to develop a directed acyclic graph 
(Weng et al. 2009) that inferred the following 
confounders: age, race, parity, education, 
and smoking (Figure 2) (Cooper et al. 2002; 
Knox et al. 2011). We did not adjust for body 
mass index (BMI; body weight in kilograms 
divided by height in meters squared) for several 
reasons. Steenland et al. (2009) reported 
an association between serum PFC levels 
and BMI, suggesting that BMI could be a 
potential intermediate on the causal pathway 
between PFC exposure and menopause. 
High BMI has also been associated with 
later onset of natural menopause (Akahoshi 
2002). However, in a study using data from 
NHANES, Nelson et al. (2010) found no 
consistent association between serum PFC 
Figure 1. Study population of women 20–65 years of age who had PFC serum measurements: NHANES 
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levels and BMI; thus, BMI did not meet 
criteria as a potential confounder (Greenland 
and Robins 1986). Because BMI generally 
increases after menopause, BMI reported at the 
time of the survey may not reflect BMI at the 
time of menopause. Therefore, we examined 
whether inclusion of BMI in our model would 
appreciably alter the association between 
PFCs and menopause (HR change > 10%) 
and found that it did not (results not shown). 
We also considered adjustment for NHANES 
wave. However, because sample wave was 
strongly associated with serum PFC levels but 
not age at menopause, it was not included 
as a covariate. Age at the time of interview 
was modeled as a continuous variable. Race/
ethnicity, education, smoking, and parity were 
modeled as categorical variables (Table 1).
Reverse causation. PFCs may be excreted 
in blood and tissue during menstruation (Knox 
et al. 2011); therefore, women who are no lon-
ger menstruating may have higher levels of 
PFCs because they lack that elimination path-
way. Consequently, any association between 
serum PFC levels and rate of natural meno-
pause may be the result of reverse causation. 
We investigated the potential for reverse causa-
tion in two ways. First, we used proportional 
hazard models to examine the association 
between PFC levels and rate of hysterectomy. 
Premenopausal women were censored at their 
age at interview, and post menopausal women 
were censored at the age of menopause. If we 
assume that the reasons for hysterectomy are 
not related to PFC exposure, an observed posi-
tive association between PFC levels and hyster-
ectomy suggests reverse causation. Conversely, 
if there is no reverse causation, we would 
expect to see no association between PFC level 
and hysterectomy. Second, we investigated 
whether the rate of natural menopause predicts 
PFC levels; if the absence of menstrual blood 
and tissue loss explains the association between 
PFCs and self-reported natural menopause, 
we would expect women who menstruated 
more recently to have lower serum levels of 
PFCs. We used generalized additive models 
(GAMs) to examine the shape of the relation-
ship between years since natural menopause 
and PFCs among post menopausal women 
and determined that a linear approxi mation 
appropriately represented the shape of the 
relationship (results not shown). We report 
results from linear regression models in SAS 
Proc SURVEYREG. Statistical significance 
was defined as p = 0.05.
Results
Among the 2,732 women with both PFC 
measure ments and menstrual status data, 
65.9% (n = 1,800) were pre menopausal, 
18.3% (n = 501) had completed natural 
menopause, and 15.7% (n = 431) had hys-
terectomies (Table 1). At the time of the 
survey, pre menopausal women were generally 
younger (median age, 34 years), and women 
who had gone through natural menopause 
were the oldest (median age, 58 years). The 
median age at last period among women 
who had completed natural menopause was 
49 years. We detected PFOS, PFOA, PFHxS, 
and PFNA in at least 95% of serum samples, 
similar to previous reports from the larger 
NHANES population (Calafat et al. 2007a, 
2007b; Kato et al. 2009). The pre menopausal 
group had the lowest median PFC levels, 












Table 1. Demographic characteristics of women 20–65 years of age who either had their period (pre-
menopausal), had experienced menopause, or had experienced hysterectomy: NHANES 1999–2000, 
2003–2004, 2005–2006, 2007–2008, and 2009–2010.a
Characteristic Premenopause Menopause Hysterectomy
Population (n) 1,800 501 431
Age at interview (years; median ± SD) 34 ± 9.61 58 ± 5.25 55 ± 8.46
Age at last period (years; median ± SD) 49 ± 4.67 38 ± 7.66
NHANES cycle 
1999–2000 282 (15.67) 67 (13.37) 48 (11.14)
2003–2004 298 (16.56) 84 (16.77) 98 (22.74)
2005–2006 403 (22.39) 83 (16.57) 75 (17.40)
2007–2008 389 (21.61) 125 (24.95) 110 (25.52)
2009–2010 428 (23.78) 142 (28.34) 100 (23.20)
Race/ethnicity 
White non-Hispanic 790 (43.89) 225 (44.91) 209 (48.49)
Black non-Hispanic 345 (19.17) 96 (19.16) 101 (23.43)
Mexican American 433 (24.06) 115 (22.95) 65 (15.08)
Other Hispanic 159 (8.83) 43 (8.58) 38 (8.82)
Other (including multi racial) 73 (4.06) 22 (4.39) 18 (4.18)
Education (years) 
< 12 440 (24.47) 158 (31.54) 112 (25.99)
12 359 (19.97) 100 (19.96) 127 (29.47)
> 12 999 (55.56) 243 (48.50) 192 (44.55)
Missing 2 0 0
BMI (kg/m2) 
Underweight (< 18.5) 46 (2.56) 6 (1.21) 4 (0.94)
Normal weight (18.5 to < 25) 569 (31.74) 129 (26.01) 72 (16.98)
Overweight (25 to < 30) 516 (28.76) 140 (28.23) 123 (29.01)
Obese (> 30) 663 (36.96) 221 (44.56) 225 (53.07)
Missing 6 5 7
Ever smoked
No 1,188 (66.00) 270 (53.89) 230 (53.36)
Yes 612 (34.00) 231 (46.11) 201 (46.64)
Missing 0 0 0
Parity (no. of live births) 
0 388 (23.08) 62 (13.11) 39 (9.24)
1 339 (20.17) 66 (14.00) 60 (14.22)
> 1 954 (56.75) 344 (72.89) 323 (76.54)
Missing 119 29 9
PFC exposure [ng/mL; median (T1, T3)]
PFOS 10.3 (6.0, 17.0) 14.03 (8.80, 23.9) 17.50 (10.6, 29.4)
PFOA 2.70 (1.80, 4.20) 3.80 (2.50, 5.30) 4.20 (2.90, 5.90)
PFNA 0.90 (0.60, 1.40) 1.20 (0.80, 1.80) 1.30 (0.80, 2.10)
PFHxS 1.00 (0.60, 1.80) 1.50 (0.90, 2.60) 1.70 (1.10, 3.10)
T, tertile. Values are n (%) except where indicated.
aWomen with unknown menopausal status were excluded. 
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whereas the post hysterectomy group had the 
highest median levels (Table 1). For women in 
our study, serum collection and completion of 
reproductive health questionnaires took place 
a median of 7.5 years after natural menopause 
[inter quartile range (IQR), 8 years] and a 
median of 14 years after hysterectomy (IQR, 
16.5 years). In addition, PFC measurements 
were available for 265 women who lacked data 
on menstrual status and for 14 who indicated 
they had not had a period in the past year but 
did not report the reason.
After adjusting for age at interview, race/
ethnicity, education, smoking status, and 
parity, women with higher serum levels of 
PFCs (tertiles 2 and 3) consistently had higher 
rates of menopause than women in tertile 1 
(Figure 3). There appeared to be a monotonic 
dose–response association of PFOA, PFNA, 
and PFHxS with menopause. The adjusted 
HRs for women with the highest serum 
levels of PFOA, PFNA, and PFHxS (tertile 3 
compared with tertile 1) were 1.36 (95% CI: 
1.05, 1.75), 1.47 (95% CI: 1.14, 1.90), and 
1.70 (95% CI: 1.36, 2.12), respectively. The 
adjusted HRs for tertile 2 versus tertile 1 were 
1.22 (95% CI: 0.92, 1.62) for PFOA, 1.43 
(95% CI: 1.07, 1.91) for PFNA, and 1.42 
(95% CI: 1.08, 1.87) for PFHxS. For serum 
PFOS, adjusted HRs were higher in tertile 2 
than in tertile 3. 
We observed robust, positive dose–
response associations for all four PFCs and 
hysterectomy (Figure 4). PFHxS was most 
strongly associated with the rate of hysterec-
tomy (adjusted HR  = 3.50; 95% CI: 2.72, 
4.50) in tertile 3. Although the HRs for 
PFOS and PFOA are lower than those for 
PFHxS, the monotonic pattern of increasing 
HRs for PFOS and PFOA appears fairly simi-
lar to that of PFHxS. Using linear regression 
models, we found that levels of all four PFCs 
increased with each additional year since 
natu ral menopause (Table 2).
Discussion
Higher body burdens of PFCs were associ-
ated with earlier onset of natural menopause. 
Associations were strongest between serum 
levels of PFNA and PFHxS and the rate of 
natural menopause. PFNA and PFHxS have 
not been studied previously with respect to 
menopause, which is of concern because 
PFNA and PFHxS have not declined over 
time in the same manner as PFOA and PFOS 
(Andersen et al. 2008; Calafat et al. 2007b; 
Kato et al. 2011); geometric mean serum lev-
els of PFNA are increasing (e.g., from 0.55 
to 1.49 ng/mL between survey years 1999–
2000 and 2007–2008), and serum levels of 
PFHxS increased in 2007–2008 compared 
with previous years (Kato et al. 2011). Results 
of the present study show positive associa-
tions between PFOS and PFOA and earlier 
menopause, consistent with previous reports 
in the literature (Knox et al. 2011). As we 
anticipated, serum levels of PFOA were lower 
in our sample (median, 3.8 ng/mL) com-
pared with the C8 Health Study (medians 
of 17.6 ng/mL in women 18 to ≤ 42 years 
of age and 23.4 ng/mL in women > 42 and 
≤ 51 years of age) (Knox et al. 2011), which 
had high levels of PFOA due to industrial 
contamination. Despite lower levels, we 
also observed a positive association between 
PFOA and the rate of natural menopause.
Although we observed associations for all 
PFCs assessed, we cannot rule out the pos-
sibility that associations are driven by a single 
congener, because some PFCs in sera are cor-
related. Using NHANES data, Calafat et al. 
(2007b) found statistically significant correla-
tions (p < 0.001) between the log-transformed 
concentrations of PFOS and PFOA [Pearson 
correlation coefficient (r) = 0.66], PFHxs 
(r = 0.56), and PFNA (r = 0.50). The correla-
tion coefficient between the log-transformed 
concentrations of PFOA and PFHxS was 
Table 2. Adjusted β (95% CI)a for the change in 
serum PFC concentrations (ng/mL) associated 
with a 1-year increase in the time between natu ral 
menopause and sample collection among natu-
rally post menopausal women (n = 501): NHANES 
1999–2000, 2003–2004, 2005–2006, 2007–2008, and 
2009–2010.
PFC β (95% CI)a
PFOS 0.23 (–0.16, 0.48)
PFOA 0.07 (0.013, 0.13)
PFNA 0.02 (0.002, 0.042)
PFHxS 0.023 (–0.019, 0.065)
aAdjusted for age at time of survey, race/ethnicity, 
education, smoking, and parity.
Figure 3. Adjusted (Adj) HRs and 95% CIs for menopause in association with tertiles (T) of serum PFCs 
among women 20–65 years of age: NHANES 1999–2000, 2003–2004, 2005, 2006, 2007–2008, and 2009–2010. 
Data are based on the proportional hazards model for age at menopause, censoring at interview age if 
still menstruating, and eliminating all cases of hysterectomy. HRs are adjusted for age at interview, race/




T1 (0.14 to 9 ng/mL) 634 1
T2 (> 9 to 18.4 ng/mL) 756 1.23 (1.04, 1.44)
T3 (> 18.4 ng/mL) 761 1.16 (0.91, 1.48)
PFOA  
T1 (0.07 to 2.5 ng/mL) 649 1
T2 (> 2.5 to 4.4 ng/mL) 723 1.22 (0.92, 1.62) 
T3 (> 4.4 ng/mL) 779 1.36 (1.05, 1.75) 
PFNA  
T1 (0.07 to 0.80 ng/mL) 668 1
T2 (> 0.80 to 1.5 ng/mL) 712 1.43 (1.07, 1.91) 
T3 (> 1.5 ng/mL) 771 1.47 (1.14, 1.90) 
PFHxS  
T1 (0.07 to 0.90 ng/mL) 621 1
T2 (> 0.90 to 1.8 ng/mL) 715 1.42 (1.08, 1.87)
T3 (> 1.8 ng/mL) 815 1.70 (1.36, 2.12) 
Exposure n Adj HR (95% CI)
Figure 4. Adjusted (Adj) HRs and 95% CIs for hysterectomy in association with tertiles (T) of serum PFCs 
among women: 20–65 years of age NHANES 1999–2000, 2003–2004, 2005, 2006, 2007–2008, and 2009–2010. 
Data are based on the proportional hazards model for age at hysterectomy, censoring at interview age if still 
menstruating, and eliminating all cases of menopause. HRs are adjusted for age at interview, race/ethnicity, 
education, smoking, and parity. 
1 5
HR
Exposure n Adj HR (95% CI)
PFOS  
T1 (0.14 to 9 ng/mL) 660 1
T2 (> 9 to 18.4 ng/mL) 706 1.44 (1.12, 1.85)
T3 (> 18.4 ng/mL) 733 2.56 (1.90, 3.43)
PFOA  
T1 (0.07 to 2.5 ng/mL) 658 1
T2 (> 2.5 to 4.4 ng/mL) 696 1.83 (1.31, 2.56)
T3 (> 4.4 ng/mL) 745 2.81 (2.12, 3.71)
PFNA  
T1 (0.07 to 0.80 ng/mL) 652 1
T2 (> 0.80 to 1.5 ng/mL) 692 1.39 (1.08, 1.80)
T3 (> 1.5 ng/mL) 755 1.78 (1.33, 2.37)
PFHxS  
T1 (0.07 to 0.90 ng/mL) 633 1
T2 (> 0.90 to 1.8 ng/mL) 683 2.22 (1.66, 2.98)
T3 (> 1.8 ng/mL) 783 3.50 (2.72, 4.50)
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0.46; between PFOA and PFNA, r = 0.55. 
In the present study, Spearman correlations 
ranged from 0.19 between PFOS and PFNA 
to 0.65 between PFOS and PFOA (p < 0.001 
for all correlations). We considered the use 
of a total (summed) exposure measure of all 
four PFC congeners; however, serum levels of 
PFOS were much higher than those of PFOA, 
PFHxS, and PFNA, suggesting that the com-
bined analysis would dis proportionately reflect 
PFOS levels.
Early menopause is associated with a num-
ber of adverse health impacts. For example, 
results from a meta-analysis demonstrated that 
menopause before 50 years of age was asso-
ciated with a 25% increased risk of cardio-
vascular disease (Atsma et al. 2006) and 
menopause before age 46 has been associated 
with increased risk of coronary heart disease 
and stroke (Lisabeth et al. 2009; Wellons et al. 
2012). If PFC levels are predictors of earlier 
menopause, exposure may also be responsible 
for increased risk of other serious health out-
comes (e.g., cardio vascular disease and stroke). 
Our examination of reverse causality 
indicated positive associations between all 
four of the PFCs we examined and the rate 
of hysterectomy, and showed that these 
PFC levels increased with time since natural 
menopause. Taken together, the results of 
these two additional analyses suggest that the 
association between PFCs and menopause 
may reflect the accumulation of PFCs among 
women who were not excreting them through 
menstruation. However, because of the cross-
sectional natural of our data, we cannot 
confirm the direction of these associations. 
Prospective human studies evaluating the 
onset of menopause are necessary to better 
assess potential causality.
Using data from the large, U.S. representa-
tive NHANES sample allowed us to explore 
the association between PFCs and the haz-
ard of natural menopause while adjusting for 
potential confounding by a number of vari-
ables. Unlike previous analyses of PFCs and 
natural menopause, NHANES collected infor-
mation on the time since natural menopause 
and surgical hysterectomy, which allowed us 
to address the potential for reverse causality. 
The cross-sectional nature of data collection 
does not allow us to establish temporality 
because menopause status, age at menopause, 
and PFC measurements were taken at the 
same time. PFC measurements were based on 
a single serum sample. Any misclassification 
from single measures would tend to decrease 
power and under estimate the real strengths 
of association (Pearce et al. 2007). Although 
a single sample may be more reliable for com-
pounds with long half-lives, samples collected 
at several time points would be more accu-
rate for classifying exposure in future studies 
(Melzer et al. 2010).
Conclusions
The consistency and robustness of our findings 
suggest a relationship between PFCs and 
menopause, although the under lying mecha-
nism of that association remains unknown. 
In these cross-sectional data, it is not clear 
whether the association observed between 
PFCs and menopause is causal, if results are 
due to non causal influences such as biases 
from confounding or misclassification, or 
if results are due to accumulation of PFCs 
after menopause. Regardless of the under lying 
cause, women appear to accumulate PFCs 
more rapidly after they are no longer menstru-
ating. These results, along with the ubiquitous 
nature of exposure and persistence of PFCs in 
the environment, support the need for contin-
ued monitoring of serum levels in the general 
popu lation as well as further studies of the 
reproductive health effects of PFCs.
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